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cBackground. Tissue-engineered pulmonary arteries could
vercome the drawbacks of homografts or prosthetic conduits
sed in the repair of many congenital cardiac defects. How-
ver, the ideal scaffoldmaterial for tissue-engineered conduits
s still subject of intensive debate. In this study, we evaluated
n acellularized allogeneic matrix scaffold for pulmonary
rtery tissue engineering with and without in-vitro reseeding
ith autologous endothelial cells in thepulmonary circulation
n a growing sheep model.
Methods. Ovine pulmonary arteries (n  10) were
cellularized by trypsin/ethylenediamine tetraacetic acid
ncubation. Autologous endothelial cells were harvested
rom carotid arteries, and the pulmonary conduits were
eeded with endothelial cells. We implanted in-vitro,
utologous, reendothelialized (group A, n  5) and
cellularized pulmonary conduits (group B, n  5) in the
ulmonary circulation. The animals were sacrificed 6
onths after the operation. Explanted valves were exam-ned histologically and by immunohistochemistry.
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2006 by The Society of Thoracic Surgeons
ublished by Elsevier IncResults. The conduit diameter increased in both groups
group A, 44%  11%; group B, 87%  18%; p < 0.05). In
roup A, however, a proportional increase in diameter
as present, whereas in group B, a disproportionate
ncrease resulting in aneurysm formation was observed.
istologically, the conduit wall integrity was destroyed
n group B and preserved in group A. In group B, the
xtracellularmatrix degenerated with a reduced amount
f collagens and proteoglycanes. Furthermore, no elastic
bers were detectable. In contrast, the extracellularmatrix
n group A was close to native ovine tissue.
Conclusions. Tissue-engineered pulmonary conduits
autologous endothelial cells and allogeneic matrix scaf-
olds) functioned well in the pulmonary circulation.
hey demonstrated an increase in diameter and an extra-
ellular matrix comparable to that of native ovine tissue.
(Ann Thorac Surg 2006;81:1466–71)
© 2006 by The Society of Thoracic Surgeonslarge proportion of children with congenital heart
defects may require implantation of conduits to
econstruct pulmonary arteries or the right ventricular
utflow tract. Currently, homograft or prosthetic con-
uits are the conduits of first choice. However, draw-
acks of these conduits are a lack of growth potential,
lack to remodel, the tendency to degenerate, and
usceptibility to infection. Thus, these children may
ace several reoperations for pulmonary artery conduit
eplacement.
Creation of bioartifical conduits based on the principal
oncept of tissue engineering with the use of preformed
caffold material with in-vitro seeding of cellular tissue
omponents could overcome the inherent problem of
omograft or prosthetic conduits. Previous studies focus-
ng on biodegradable polymer scaffolds for tissue engi-
eering of heart valve and pulmonary artery resulted in
ormations with abnormal extracellular matrix (ECM)
1-5). In-vivo and in-vitro studies with acellularized allo-
ccepted for publication Aug 29, 2005.
resented at the Fortieth Annual Meeting of The Society of Thoracic
urgeons, San Antonio, TX, Jan 26–28, 2004.
ddress correspondence to Dr Leyh, Division of Thoracic and Cardiovas-eneic matrix proofed the concept of biological matrices
or the generation of viable cardiac tissue [6–8]. How-
ver, only limited data are provided on acellularized
iological scaffolds for tissue-engineered pulmonary ar-
eries. The purpose of this study was to evaluate the
oncept of tissue-engineered pulmonary arteries based
n an allogeneic scaffold in a large growing animal model
ith an implantation period as long as 6 months.
aterial and Methods
cellularization of Pulmonary Artery Bifurcations
vine pulmonary artery bifurcations (n  10) were ob-
ained from immature sheep (16  2 kg) under sterile
onditions. Conduits were stored at 4°C. Within 30 min-
tes the conduits were acellularized in a bioreactor. The
ioreactor was filled with 0.05% trypsin (Biochrom KG,
erlin, Germany) and 0.02% ethylenediamine tetraacetic
cid (EDTA [Biochrom]) for 48 hours, followed by phos-
hate-buffered saline (PBS) flushing for 48 hours to
emove cell debris. All steps were conducted in an
tmosphere of 5% CO2 and 95% air at 37°C with the
ioreactor rotating at a speed of 7 rpm. Samples of the
onduit were taken before and after treatment to verify
omplete acellularization.
0003-4975/06/$32.00
doi:10.1016/j.athoracsur.2005.08.083
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Rell Isolation and Culture
he techniques of cell isolation and cell culturing have
een described in detail elsewhere [9]. Autologous cells
ere retrieved from short segments of the right carotid
rtery, which were harvested from five lambs (14  2 kg),
hich were planned for subsequent implantation.
ell Seeding
cellularized conduits (group A, n  5) were coated with
ndothelial cells, resulting in a uniform cellular restitu-
ion of the pulmonary conduit surface. Three separate
ycles of endothelial cell seedings were performed. In
ach cycle 1  106 endothelial cells were seeded onto the
ulmonary conduit scaffold fixed into a bioreactor and
ultured in static nutrient medium (DMEM, Gibco BRL
ife Technologies, Gaithersburg, MD) for 4 hours (37°C,
% CO2), followed by rotation of the bioreactor (12 hours,
.1 rpm). Samples of the conduit were taken to prove
eeding of endothelial cells.
urgical Techniques
he in-vitro reseeded pulmonary conduits were im-
lanted into the same 5 sheep, from which the carotid
rteries were harvested initially (group A). The acellular-
zed conduits were implanted in the remaining 5 sheep
group B). The mean weight of immature sheep
mounted to 16.3  2 kg. Anaesthesia was induced with
0 mg/kg of ketamine and maintained with an intrave-
ous bolus injection of 2 mg/kg propofol. The heart was
xposed by a left anterolateral thoracotomy entering the
hest through the fourth intercostal space. Systemic an-
icoagulation was induced with heparin (400 IU/kg). After
annulation of the femoral arteries and right atrium, a
ormothermic cardiopulmonary bypass was established.
n bypass, 0.01 mg/kg fentanyl and 0.02 mg/kg pancu-
onium were administered. With the heart beating, the
ain pulmonary artery was transected, and the pulmo-
ary trunk removed. The conduits were orthotopically
mplanted by using running 5-0 monofilament sutures
Prolene; Ethicon, Somerville, New Jersey). Heparin was
eversed with 300 IU of protamine per kilogram after
eaning from bypass. The chest was closed in layers
sing resorbable sutures. An intercostal nerve block with
.25% bupivacaine was administered. No further antico-
gulation was applied. All animals received cefazolin,
,000 mg daily, for the first postoperative week. For pain
ontrol, intramuscular buprenorphin injections were per-
ormed during the first 3 days and later as required. All
nimals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals”
ublished by the National Institutes of Health (NIH
ublication 85-23, revised 1985). The animals were sacri-
ed after 6 months.
ostoperative Evaluation
he animals were examined by echocardiography imme-
iately after the operation, and before termination. After
ermination, specimens of conduit wall were prepared for
istology and immunohistochemistry. eCHOCARDIOGRAPHY. Epicardial echocardiography examina-
ions were performed immediately after the operation, and
efore termination (Sonos 5500 Cardiac Imager, 7.5-MHz
hased-arrayed transducer; Hewlett-Packard; Agilent
echnologies, Palo Alto, CA) to evaluate conduit diameter.
hanges in diameter were expressed as percentage. The
ative pulmonary trunk, to which the allogeneic pulmonary
rtery conduit was attached, served as the reference diam-
ter for evaluation of postoperative allogeneic pulmonary
onduit diameter. Proportional increase in diameter: diam-
ter of the implanted allogeneic pulmonary conduit at the
ime of termination equals the diameter of the native
ulmonary trunk at the time of termination. Disproportion-
te increase in diameter: diameter of the implanted alloge-
eic pulmonary conduit at the time of termination ex-
eeded the diameter of the native pulmonary trunk bymore
han 20% at the time of termination.
IABILITY TEST. To verify the viability of endothelial cells
fter in-vitro repopulation, circular segments were ex-
ised before implantation and examined by a live-dead
ssay. A commercially available cell viability assay based
n simultaneous determination of live and dead cells was
sed (Live/Dead Viability/Cytotoxity Kit for Animal
ells; Molecular Probes; Invitrogen GmbH, Karlsruhe,
ermany).
ISTOLOGY. For determination of cellular and extracellular
omponents of the pulmonary conduits, histologic stain-
ng and histochemical assays were performed. Histologic
haracterization of conduit matrix components was con-
ucted by means of standard hematoxylin-eosin, Movat
entachrome, and van Giesson staining. Histologic com-
arison between explanted pulmonary artery tissue and
ative ovine pulmonary artery tissue was performed.
onduit wall integrity was defined as a histologic com-
osition of the ECM in terms of cellularity, and semi-
uantitative reduced amounts of stainable collagen, gly-
osaminoglycans, proteoglccans, and stainable elastin
bers comparable with native ovine pulmonary artery
issue.
MMUNOHISTOLOGY. Snap-frozen conduit wall specimens
ere used for immunohistologic analysis. Immunohisto-
hemical staining for endothelial cell characterization
as performed by applying the avidin-biotin-peroxidase
echnique. Endothelial cells were characterized by the
resence of factor VIII-related antigens (primary anti-
ody, v. Willebrandt factor; clone 8/86, DAKO Diagnos-
ika, Hamburg, Germany). A goat anti-mouse antibody
DAKO) served as a secondary antibody. Negative con-
rols were simultaneously performed. Normal mouse or
abbit serum served as a primary antibody and a specific
ouse or rabbit antibody served as the secondary
ntibody.
esults
ll animals survived the operative procedure and recov-
red uneventfully.
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Rchocardiographic Findings
fter 6 months, the conduits showed no evidence of throm-
us formation or calcification in either group. All conduits
howed an increase in diameter compared with the time of
mplantation. In group A, however, a proportional increase
n diameter was present, whereas in group B, a dispropor-
ionate increase was observed (group A; 44% 11%, group
; 87%  18%; p  0.05; Fig 1).
istologic Examination
he viability test of specimen taken immediately before
mplantation of the in-vitro repopulated conduits re-
ealed viable endothelial cells. Hematoxylin-eosin stain-
ng of the conduits after explantation showed a complete
ndothelial lining in all conduits after 6 months. An
ncrease in cellular repopulation of the valve interstitium
as observed in group A, indicating an increased cell
urnover. The characterization and semiquantification of
onduit matrix components showed normal amounts of
tainable collagen, elastin, glycosaminoglycans, and pro-
eoglycans content in group A. Although the in-vitro
epopulation resulted in a tissue formation resembling
ig 1. Allogeneic pulmonary conduits after 6 months in-situ. (A)
n-vitro reendothelialized conduits; the explanted conduits showed a
iameter and normal appearance of the pulmonary arterial wall. (B)
cellularized implanted conduits; gross dilatation of the pulmonary
onduit with a thin aneurysmatic arterial wall.ative ovine tissue, the increased cellularity of the ECM could either indicate that the repopulation process is a
till ongoing process or the beginning of a fibrosis. In
ontrast, in group B, a decreased cellular repopulation of
he interstitium was observed. The Movat pentachrome
tain showed a severe degenerated ECM with reduced
mouts of stainable collagen, glycosaminoglycans, and
roteoglycans, and no stainable elastin fibers (Fig 2).
mmunohistochemical Staining
actor VIII stained cells were found in all conduits on the
nternal surface of the pulmonary conduits (Fig 3).
omment
n this study, we have shown that the implantation of
n-vitro reendothelialized allogeneic pulmonary conduits
ig 2. Movat pentachrome stain of the extracellular matrix of allo-
eneic pulmonary conduits after explantation. (A) In-vitro reendo-
helialized implanted conduit after 6-month implantation period,
ith normal content of collagen (yellow), elastic fibers (red), and
roteoglycanes (bright blue) resembling native ovine pulmonary ar-
ery tissue but with increased cellularity. (B) Pathologic composition
f the extracellular matrix acellularized implanted conduits after 6
onths with reduced collagen (yellow) and proteoglycane (bright
lue) content and no stainable elastin fibers. Furthermore, a de-
reased interstitial cellularity is shown.
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Reads to viable and well-functioning pulmonary artery con-
uits in an immature growing sheep model. Follow-up
xaminations for as long as 6 months after implantation
esulted in an ECM composition resembling native ovine
ulmonary artery tissue. Furthermore, we were able to
etect a proportional increase of the conduit diameter.
The durability of conduits for use in children with
ongenital heart disease is limited because neither ho-
ografts nor synthetic grafts have growth potential. That
ay lead to a progressive increase in pressure gradients
ver time, necessitating reoperation for replacement of
tenotic conduits [10, 11].
Several groups have been focusing on engineering
onduits, which should be vital, nonthrombogenic pro-
iding growth potential [5, 12–15]. Only Shinoka and
oworkers [5] created a viable conduit following the
rinciples of tissue engineering using a three-
imensional synthetic polyglycol acid fibers matrix that
as repopulated in vitro with autologous endothelial
ig 3. Hematoxylin-eosin and van Willebrandt factor staining of
xplanted allogeneic pulmonary conduits after 6 months. (A) In-vitro
eendothelialized pulmonary conduit; normal endothelial cell mono-
ayer. (B) Acellularized allogeneic conduits 6 months after implanta-
ion, showing normal endothelial cell monolayer.ells, fibroblasts, and smooth muscle cells. Although the tonduits functioned well in the pulmonary circulation for
s long as 169 days, the analysis of conduits showed an
bnormal low collagen content and an increase in the
alcium content within the ECM [5]. A tissue-specific
CM is a prerequisite for normal cell metabolism, cellu-
ar function, interaction, and adhesion [16–18]. The ab-
ence of an extracellular molecular network and of ECM
roteins, responsible for cellular attachment, in biode-
radable polymer scaffolds, might result in a disturbed
ell-to-ECM interaction. This could explain the abnormal
ollagen, elastin, and glycosaminoglycan concentration
n the ECM of tissue-engineered cardiac tissue based on
iodegradable polymer scaffolds [1–5]. The consequences
f an abnormally composed ECM are manifold. The
ifferent matrix ECM components are mutually depen-
ant; furthermore, these components may influence the
bility of regeneration and the function of the matrix.
ence, it can be speculated that an abnormal ECM
omposition may lead to premature degenertation of
issue-engineered conduits. In addition, a potential prob-
em of polymer scaffold is the lack of extracellular matrix
roteins, which play a pivotal role in physiological cell-
o-cell and cell-to-ECM interaction.
Acellularized allogeneic matrix scaffolds have already
hown superior adhesive properties of endothelial cells,
nd in-vivo studies proofed the concept of biological ma-
rices for generation of viable cardiac tissue [6–9]. The
egeneration of the acellularized implanted conduits in this
tudy clearly demonstrate that in-vitro repopulation with
ndothelial is mandatory to create viable and functioning
onduit. It can be speculated that the endothelial cells lining
he luminal surface of the conduit create a protecting
arrier for the extracellular matrix; this could guarantee a
estricted migration of fibroblasts and myocytes. Thus, a
ontrolled remodeling and regeneration of the allogeneic
atrix and replacement of the allogeneneic matrix proteins
ith autologous matrix proteins may result.
Previously, we have shown that the source of biological
cellularized tissue (xenogeneic versus allogeneic) has an
mpact on the quality of tissue-engineered cardiac tissue [19].
n the previous study, however, we applied a static acellular-
zation process in contrast to the dynamic acellularization
rocess used in this study. Hence, there is evidence that the
cellularization process influence the quality of tissue-
ngineered cardiac tissue, based on biological three-
imensional scaffolds. The degenerated tissues of acellular-
zed implanted pulmonary conduits resulted in aneurysm
ormation, in contrast to the in-vitro reendothelialized con-
uits, and a proportional increase in diameter could be ob-
erved. This finding is in concert with the findings of Simon
nd coworkers [20]. In a clinical study, implantation of acellu-
arized xenogenic Synergraft conduits resulted in a strong
nflammatory response and no repopulation of the grafts with
uman cells, resulting in conduit failure in 3 patients with one
ethal conduit rupture at the seventh postoperative day due to
tructural disintegration of the graft [20]. Although implanta-
ion of in-vitro reendothelialized conduits resulted in a tissue
ormation resembling native ovine tissue, an increased cellu-
arity was observed, which could indicate an increased cell
urnover within the ECM, finally resulting in fibrosis.
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RWe would like to emphasize that these data do not
ndicate that clinical use of acellularized in-vitro repop-
lated allogenic pulmonary arteries is justified at this
ime. In this context, it is important to recall the data
ublished by Simon and coworkers [20], who reported on
arly failure of xenogeneic acellularized conduits in pe-
iatric patients, with sudden death for 3 of 4 patients; in
ll deaths, the Synergraft was severely degenerated—
ndicating that premature implantation of tissue-
ngineered grafts may have catastrophic results.
In conclusion, the results of this study demonstrate
hat a more detailed knowledge of tissue development is
andatory to generate viable and functioning pulmo-
ary artery conduits withstanding physiologic stress in
he pulmonary circulation in the long run. Although
n-vitro reendothelialized conduits revealed viable and
unctioning conduits tissue for as long as 6 months, it can
ot be excluded that these conduits will degenerate.
urther studies with different scaffold materials, cell
ypes, in-vitro reseeding protocols, and longer follow-up
eriods are mandatory until tissue-engineered conduits
an be implanted clinically.
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patients. Eur Cardiothoracic Surg 2003, 23:1002–6.ISCUSSIONR ANDREW C. FIORE (St. Louis, MO): When you seeded
hese allografts, did you use any kind of cell labeling techniques
o identify the fact that those seeded cells were intact in the
llograft conduit?
R LEYH: Thank you very much for the kind question. Well, we
ctually did not label these cells. But what we did is, actually, in
nother experience,weexplanted these conduits after 1hour, 12hours
nd24hours, andweare still able to see endothelial cells in the in vitro
epopulated conduit. In contrast to the acellularized conduits,wewere
ot able todetect any cells after 24hours. But anyway,wehavenodata
hether these cells, we actually found after explantation, are still the
ells we seeded onto before implantation.
R HENRY L. WALTERS III (Detroit, MI): You pointed out oneegenerate. Another disadvantage, of course, is their relative
ack of availability, especially in certain sizes. I assume that the
linical application of your scheme in humans would again
nvolve harvesting cadaveric allografts; therefore, availability
ould still be a problem. Is this the direction that we should
ursue in tissue engineering as opposed to trying to develop
caffolding materials such as PGA, chitosan, and so forth, which
s something we’re working on in our laboratory?
Also, have you tried to harvest allograft pulmonary arteries
ith valves and submit them to the same kind of treatment?
R LEYH: Well, with respect to your first question, obviously,
his is the kind of initial study where we proved the concept of
issue engineering with regard to scaffold material. So I think
ndothelial cells that are obtained from the carotid artery is not
proper way for clinical use. Our sources might be more
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Rpplicable, like progenitor cells or any other cells; but there is
till a lot of work to do in this field.
Coming to the second question, yes, we used the same
oncept for pulmonary arteries or for tissue engineering of
ulmonary conduits with a valve-sparing conduit. But when we
sed this concept, we used a synergetic scaffold material; and we
lmost found similar results.
R FIORE (St. Louis, MO): I just want to ask you one other
uestion. From your experience, what do you think the most
ptimal source of autologus endothelial cells should be?
R LEYH: Honestly, I can’t answer your question. But I believe
hat endothelial cells are not the optimal source for tissue
ngineering. Other cells might be much better.
R SCOTT M. BRADLEY (Charleston, SC): You showed that
oth the in-vitro and the in-vivo approach led to an endothe-
ial cell layer when you removed the conduits. Could you give js some thoughts on why, if both the conduits acquire an
ndothelial layer, the in-vitro conduits had such a markedly
mproved extracellular matrix. Is it a time effect, or is it
omething else?
R LEYH: There might be sort of a time effect associated with
he results presented. I believe that, in my opinion, the in-vitro
eeding with endothelial cells may have sort of a protective
echanism on the extracellular matrix, since the material sort of
reserved interaction between the matrix and the endothelial
ells.
And that might result, or it’s just a hypothesis, this can
esult in a sort of controlled migration of cells within the
atrix, so that controlled tissue regeneration will take place
n these conduits. And in contrast, if there are no cells, then
aybe it’s sort of uncontrolled migration of cells into a matrix,
nd this might result in degeneration of the matrix. But it’s
ust a hypothesis.
